Discover 776 paid clinical trials in Round Rock, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 776
Mothers and CareGivers Investing in Children Study 2.0
A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)
Location: Austin TX, Cincinnati OH, Chicago IL, Columbus OH,
Sponsor: Sanofi
Sex: All
Age: 0 - 2
Code: NCT06192576
Recruiting
Quality of End-of-Life Care for Children With Cancer
for
Childhood Hematopoietic and Lymphatic System Neoplasm,
Location: Austin TX, Dallas TX, Little Rock AR, Kansas City MO,
Sponsor: Children's Oncology Group
Sex: All
Age: 18+
Code: NCT07412002
Recruiting
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
for
Locally Advanced Adrenal Cortical Carcinoma,
Location: Austin TX, San Antonio TX, Fort Worth TX, Dallas TX,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 12+
Code: NCT06900595
Phase2, Recruiting
Minima Stent System Post- Approval Study (PAS)
for
Pulmonary Artery Stenosis, Aortic Coarctation
Location: Austin TX, Dallas TX, Saint Louis MI, Aurora CO,
Sponsor: Renata Medical
Sex: All
Age: 0+
Code: NCT06828770
Recruiting
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
for
Ig-E Mediated Food Allergy
Location: Austin TX, Houston TX, Little Rock AR,
Sponsor: RAPT Therapeutics, Inc.
Sex: All
Age: 12 - 55
Code: NCT07220811
Phase2, Recruiting
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
for
Rhabdomyosarcoma
Location: Austin TX, San Antonio TX, Dallas TX, Corpus Christi TX,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 50
Code: NCT07466316
Phase3, Recruiting
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)